OU Health Stephenson Cancer Center earns Center of Excellence for Rectal Cancer accreditation

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Vol.51 No.04

Clinical Roundup

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Bristol Myers Squibb announced results of an analysis from the three-arm phase III CheckMate-8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy across all lines of therapy, including first-line, for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. At a median follow-up of 47 months, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in the dual-primary endpoint of progression-free survival as assessed by Blinded Independent Central Review versus Opdivo monotherapy (HR 0.62; 95% CI 0.48–0.81; P = 0.0003).

January 31, 2025

Vol.51 No.04

Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer

FDA approved sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

January 17, 2025

Vol.51 No.02

Clinical Trials & Tribulations

New colorectal cancer screening strategies must advance the standard of care

Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical for reducing incidence and preventing deaths from this disease.

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA granted accelerated approval to encorafenib (Braftovi) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

January 10, 2025

Vol.51 No.01

OU Health Stephenson Cancer Center earns Center of Excellence for Rectal Cancer accreditation

YOU MAY BE INTERESTED IN

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer

New colorectal cancer screening strategies must advance the standard of care

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

Renew today!

Subscriber content

Never miss an issue!

Login